ADAM8、EGFR在非小细胞肺癌中的表达及其相关性  

Expression and Clinical Significance of A Disintegrin and Metalloprotease 8(ADAM8) and Epidermal Growth Factor Receptor(EGFR) in Non-small Cell Lung Cancer

作　　者：吴国成[1] 胡华成[1] 施敏骅[1] 

机构地区：[1]苏州大学附属第二医院呼吸科,江苏苏州215006

出　　处：《癌症》2008年第8期874-878,共5页Chinese Journal of Cancer

基　　金：苏州大学青年教师研究基金(No.Q3123640)~~

摘　　要：背景与目的:去整合素-金属蛋白酶8(a disintegrin and metalloprotease 8,ADAM8)表达增高与肿瘤的发生、发展、侵袭、转移密切相关,但有关其在肺癌中的表达报道较少,尤其非小细胞肺癌(non-small cell lung cancer,NSCLC)中ADAM8与表皮生长因子受体(epidermal growth factor receptor,EGFR)相关性的研究目前尚未见报道。本研究旨在探讨ADAM8和EGFR在人NSCLC中的表达水平,并分析两者的相关性。方法:应用组织芯片(tissue microarray)结合免疫组化法(immunohistochemmistry)检测ADAM8与EGFR在49例肺癌组织、28例癌旁肺组织及13例肺良性病变组织中的表达情况,并分析两者的相关性及其与各病例的临床病理因素之间的关系。结果:ADAM8、EGFR蛋白的阳性表达主要定位在胞浆和胞膜。ADAM8、EGFR在NSCLC组织中的阳性率(73.5%、69.4%)显著高于癌旁组织(10.7%、14.2%)及肺良性病变组织(15.4%、23.1%)(P<0.01)。ADAM8、EGFR在鳞癌(73.1%、65.4%)与腺癌(80.0%、75.0%)的阳性率差异无统计学意义(P>0.05)。ADAM8、EGFR在N1-N3期NSCLC的阳性率(85.7%、82.8%)显著高于N0期NSCLC(42.8%、35.7%)(P<0.01)。ADAM8、EGFR在Ⅲ～Ⅳ期NSCLC(90.0%、90.0%)的阳性率显著高于Ⅰ～Ⅱ期(62.1%、65.5%)(P<0.05)。ADAM8和EGFR的表达具有一致性,Kappa值为0.522;两者表达呈正相关(r=0.589,P<0.01)。结论:ADAM8与EGFR在NSCLC组织中的表达均增高,两者具有较高的一致性。BACKGROUND ＆ OBJECTIVE. Up-regulation of a disintegrin and metalloprotease 8 （ADAM8） is correlated with genesis, progression, invasion, and metastasis of tumors. However, the expression of ADAM8, especially its correlation to epidermal growth factor receptor （EGFR）, has seldom been reported in non-small cell lung cancer （NSCLC）. This study was to investigate expressions of ADAM8 and EGFR in NSCLC, and to analyze their correlations. METHODS; Expressions of ADAM8 and EGFR in 49 specimens of NSCLC, 28 specimens of adjacent lung tissues and 13 specimens of benign lung tissues were detected using tissue microarray （TMA） and immunohistochemmistry （IHC）. The interrelationship between the two factors and their correlations to clinicopathologic features of NSCLC were analyzed. RESULTS. ADAM8 and EGFR were mainly expressed in the cytoplasm and on the cell membrane. The positive rates of ADAM8 and EGFR were significantly higher in NSCLC than in adjacent lung tissues and benign lung tissues （73.5% vs. 10.7% and 15.4%, 69.4% vs. 14.2% and 23.1%, P〈0.01）. The positive rates of ADAM8 and EGFR were slightly lower in squamous cell carcinoma than in adenocarcinoma （73.1% vs. 80.0%, 65.4% vs. 75.0%, P〉0.05）, while were significantly higher in stage N1-N3 NSCLC than in stage NO （85.7% vs. 42.8%, 82.8 vs. 35.7%, P〈0.01） and significantly higher in stage Ⅲ -Ⅳ NSCLC than in stage Ⅰ - Ⅱ （90.0% vs. 62.1%, 90.0% vs. 65.5%, P〈0.05）. The expression of ADAM8 was positively correlated to EGFR （r=0.589, P〈0.01）, with a kappa value of 0.522. CONCLUSION. ADAM8 and EGFR are overexpressed in NSCLC, and their expressions are consistent.

关 键 词：去整合素-金属蛋白酶8 表皮生长因子受体 肺肿瘤 癌-非小细胞 

分 类 号：R734.2[医药卫生—肿瘤]